A global survey of healthcare executives finds significant satisfaction in mobile device programs, but a lack of faith in mHealth security.
To diagnose cancer, doctors use a bunch of complex examinations like an MRI, a CT scan, a biopsy or a lengthy blood test. Because of the sophisticated machines and equipment needed for these techniques and procedures, they are only conducted in the hospital setting. One startup is about to change this with its portable cancer-detecting device.
The FDA today approved the first medical device to harness artificial intelligence for the detection of diabetic retinopathy in adults who have diabetes.
A new Blockchain platform has seemingly proven that it is possible to for AI to perform more accurate health diagnosis than human doctors, paving the way for a change in the way medical tests are performed.
Unified cloud-based eClinical platforms, with built-in scalability and modularity, will drive growth opportunities across the globe
The healthcare leader relies on digital platforms, a closer relationship with IBM to continue to fast-forward care.
The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.
Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. Wilson is a Swedish biopharma developing novel therapies for patients with rare copper-mediated disorders.
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.